China Pharma Holdings (CPHI) EBT Margin (2010 - 2026)
China Pharma Holdings (CPHI) posted EBT Margin of 116.23% for Q1 2026, down 16.6% on a QoQ basis from 99.68% in Q4 2025, and down 4709.0% year-over-year from 2.52% in Q1 2025.
China Pharma Holdings (CPHI) EBT Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings' EBT Margin history runs 17 years deep, the most recent figure standing at 116.23% for Q1 2026.
- Quarterly EBT Margin fell 4709.0% year-over-year to 116.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 88.82% (up 1748.0% YoY) and the FY2025 annual result came in at 76.91%, up 2767.0% from the prior year.
- EBT Margin was 116.23% for Q1 2026 at China Pharma Holdings, down from 99.68% in the prior quarter.
- Across five years, EBT Margin topped out at 24.28% in Q1 2023 and bottomed at 155.48% in Q2 2024.
- A 5-year average of 72.89% and a median of 64.18% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 10147 bps — and 2025, when it soared 10397 bps.
- China Pharma Holdings' EBT Margin stood at 43.28% in 2022, then sank by 32 bps to 57.32% in 2023, then tumbled by 88 bps to 107.98% in 2024, then climbed by 8 bps to 99.68% in 2025, then dropped by 17 bps to 116.23% in 2026.
- Business Quant data shows CPHI's EBT Margin at 116.23% in Q1 2026, 99.68% in Q4 2025, and 86.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -116.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -116.23% |
| Dec 31, 2025 | -99.68% |
| Sep 30, 2025 | -86.15% |
| Jun 30, 2025 | -51.51% |
| Mar 31, 2025 | -69.13% |
| Dec 31, 2024 | -107.98% |
| Sep 30, 2024 | -101.61% |
| Jun 30, 2024 | -155.48% |
| Mar 31, 2024 | -69.78% |
| Dec 31, 2023 | -57.32% |
| Sep 30, 2023 | -43.12% |
| Jun 30, 2023 | -54.02% |
| Mar 31, 2023 | -24.28% |
| Dec 31, 2022 | -43.28% |
| Sep 30, 2022 | -40.22% |
| Jun 30, 2022 | -55.07% |
| Mar 31, 2022 | -64.18% |
| Dec 31, 2021 | -33.94% |
| Sep 30, 2021 | -41.78% |
| Jun 30, 2021 | -34.14% |